Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment
This study analyzed data from the Myasthenia Gravis Patient Registry to assess the disability and treatment of patients with MG. The registry collects voluntary patient-submitted data on disease management and quality of life. The analysis revealed that many MG patients experience moderate to severe impairment in health-related quality of life. The most common treatments reported were pyridostigmine, corticosteroids, mycophenolate mofetil, and azathioprine. Intravenous immunoglobulin and plasma exchange were also used by a significant number of patients. Despite these treatments, many patients continue to be negatively impacted by the disease. The study highlights the need for better understanding and management of MG in everyday clinical practice.